Effects of Ro 24-4736 in antagonizing the platelet and bronchoconstrictor responses to PAF.
O'Donnell
M
M
Department of Pharmacology, Hoffmann-La Roche, Inc., Nutley, New Jersey 07110.
D000818:Animals; D001667:Binding, Competitive; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D016084:Bronchoconstriction / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000494:pharmacology*; D004285:Dogs; D006168:Guinea Pigs; D006801:Humans; D010617:Phenanthridines / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D014227:Triazines / Q000494:pharmacology*
D001993:Bronchodilator Agents; D010617:Phenanthridines; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D014227:Triazines; C039351:platelet activating factor receptor; C071318:Ro 24-4736